

CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) plus ipilimumab (IPI) versus nivolumab (NIVO) plus sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)

Annals of Oncology

30, v874-v875

DOI: [10.1093/annonc/mdz394.029](https://doi.org/10.1093/annonc/mdz394.029)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors. <i>Antibodies</i> , 2019, 8, 51.	1.2	32
2	Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers. <i>Cancers</i> , 2019, 11, 1926.	1.7	27
3	Immune Therapy for Liver Cancers. <i>Cancers</i> , 2020, 12, 77.	1.7	49
4	Current strategies for the treatment of intermediate and advanced hepatocellular carcinoma. <i>Cancer Treatment Reviews</i> , 2020, 82, 101946.	3.4	104
5	Immunotherapy for Hepatocellular Carcinoma: A 2021 Update. <i>Cancers</i> , 2020, 12, 2859.	1.7	92
6	Nivolumab in Advanced Hepatocellular Carcinoma: Safety Profile and Select Treatment-Related Adverse Events From the CheckMate 040 Study. <i>Oncologist</i> , 2020, 25, e1532-e1540.	1.9	13
8	Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma. <i>Targeted Oncology</i> , 2020, 15, 773-785.	1.7	12
9	Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives. <i>Cancers</i> , 2020, 12, 3025.	1.7	55
10	Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma. <i>Vaccines</i> , 2020, 8, 616.	2.1	47
11	Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma. <i>JAMA Oncology</i> , 2020, 6, e204930.	3.4	124
12	LPCAT1 functions as a novel prognostic molecular marker in hepatocellular carcinoma. <i>Genes and Diseases</i> , 2022, 9, 151-164.	1.5	8
13	Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now?. <i>Vaccines</i> , 2020, 8, 578.	2.1	16
14	Immuno-oncology for Hepatocellular Carcinoma. <i>Clinics in Liver Disease</i> , 2020, 24, 739-753.	1.0	8
15	Effect of urea cream on sorafenib-associated hand-foot skin reaction in patients with hepatocellular carcinoma: A multicenter, randomised, double-blind controlled study. <i>European Journal of Cancer</i> , 2020, 140, 19-27.	1.3	13
16	Safety and Efficacy of Locoregional Treatment during Immunotherapy with Nivolumab for Hepatocellular Carcinoma: A Retrospective Study of 41 Interventions in 29 Patients. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 1729-1738.e1.	0.2	27
17	Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 73, 1460-1469.	1.8	254
18	Programmed cell death protein 1 (PD-1)-inhibition in hepatocellular carcinoma (HCC): a single center experience. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 1057-1062.	0.6	15
19	Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade. <i>Cancers</i> , 2020, 12, 1862.	1.7	47

#	ARTICLE	IF	CITATIONS
20	A Paradigm Change in the Treatment Strategy for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2020, 9, 367-377.	4.2	22
21	Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 4317-4345.	0.8	350
22	Current perspectives on the tumor microenvironment in hepatocellular carcinoma. <i>Hepatology International</i> , 2020, 14, 947-957.	1.9	46
23	Role of Immune Checkpoint Inhibitors in Gastrointestinal Malignancies. <i>Journal of Clinical Medicine</i> , 2020, 9, 2533.	1.0	15
24	Management of low-grade serous ovarian neoplasm in the setting of fertility preservation. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1834-1839.	1.2	1
25	Expression and clinical significance of LAG-3, FGL1, PD-L1 and CD8+T cells in hepatocellular carcinoma using multiplex quantitative analysis. <i>Journal of Translational Medicine</i> , 2020, 18, 306.	1.8	88
26	Atezolizumab and Bevacizumab in Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2020, 383, 693-695.	13.9	16
27	Molecular Targets, Pathways, and Therapeutic Implications for Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5232.	1.8	7
28	Immuno-Oncotherapeutic Approaches in Advanced Hepatocellular Carcinoma. <i>Vaccines</i> , 2020, 8, 447.	2.1	19
29	Novel Therapies for Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 3049.	1.7	2
30	New advances in the diagnosis and management of hepatocellular carcinoma. <i>BMJ, The</i> , 2020, 371, m3544.	3.0	210
31	Update on the Genetics of and Systemic Therapy Options for Combined Hepatocellular Cholangiocarcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 570958.	1.3	8
32	Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD-1/PD-L1 Checkpoint Blockade. <i>Cancers</i> , 2020, 12, 3048.	1.7	37
33	Immune Checkpoint Inhibitors as Monotherapy or Within a Combinatorial Strategy in Advanced Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6302.	1.8	16
34	Liquid biopsy in the clinical management of hepatocellular carcinoma. <i>Gut</i> , 2020, 69, 2025-2034.	6.1	77
35	Clinical Outcomes and Prognosis Factors of Nivolumab Plus Chemotherapy or Multitarget Tyrosine Kinase Inhibitor in Multi-Line Therapy for Recurrent Hepatitis B Virus-Related Hepatocellular Carcinoma: A Retrospective Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 1404.	1.3	8
36	Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study. , 2020, 8, e001033.		46
37	Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma. , 2020, 8, e000987.		70

#	ARTICLE	IF	CITATIONS
38	Atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma. <i>Lancet Oncology</i> , The, 2020, 21, e412.	5.1	23
39	Gd-EOB-DTPA-MRI Could Predict WNT/ $\beta^2$ -Catenin Mutation and Resistance to Immune Checkpoint Inhibitor Therapy in Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2020, 9, 479-490.	4.2	42
40	&lt;p&gt;Combination Antiangiogenic and Immunotherapy for Advanced Hepatocellular Carcinoma: Evidence to Date&lt;/p&gt;. <i>Journal of Hepatocellular Carcinoma</i> , 2020, Volume 7, 133-142.	1.8	29
41	Hepatocellular Carcinomaâ€œCirculating Tumor Cells Expressing PDâ€œL1 Are Prognostic and Potentially Associated With Response to Checkpoint Inhibitors. <i>Hepatology Communications</i> , 2020, 4, 1527-1540.	2.0	60
42	Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials. <i>ESMO Open</i> , 2020, 5, e000797.	2.0	18
43	Translational Considerations to Improve Response and Overcome Therapy Resistance in Immunotherapy for Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 2495.	1.7	12
44	Clinical and Genetic Tumor Characteristics of Responding and Non-Responding Patients to PD-1 Inhibition in Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 3830.	1.7	47
46	Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities. <i>Frontiers in Immunology</i> , 2020, 11, 598877.	2.2	133
47	Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2020, 9, 629-639.	4.2	20
48	Sequential systemic treatment in patients with hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 205-212.	1.9	17
49	Navigating the new landscape of secondâ€œline treatment in advanced hepatocellular carcinoma. <i>Liver International</i> , 2020, 40, 1800-1811.	1.9	33
50	Atezolizumab plus Bevacizumab â€œ A Landmark in Liver Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 1953-1955.	13.9	44
51	Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. <i>Lancet Oncology</i> , The, 2020, 21, 808-820.	5.1	371
52	Combined immunotherapy and VEGF-antagonist in hepatocellular carcinoma: a step forward. <i>Lancet Oncology</i> , The, 2020, 21, 740-741.	5.1	8
53	Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2020, 382, 1894-1905.	13.9	3,828
54	Antiâ€œPD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infectionâ€œRelated Advanced Hepatocellular Carcinoma: A Literature Review. <i>Frontiers in Immunology</i> , 2020, 11, 1037.	2.2	55
55	Resolution of a hepatoduodenal fistula after nivolumab treatment in a patient with hepatocellular carcinoma: challenges in immunotherapy. <i>Acta Clinica Belgica</i> , 2022, 77, 108-112.	0.5	4
56	Relationship Between Progressionâ€œFree Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PDâ€œ1/PDâ€œL1 Immune Checkpoint Blockade: A Metaâ€œAnalysis. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 1274-1288.	2.3	27

#	ARTICLE	IF	CITATIONS
57	Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis. <i>Hepatology International</i> , 2020, 14, 765-775.	1.9	37
58	Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design. <i>Future Oncology</i> , 2020, 16, 1525-1536.	1.1	50
59	Observing Durable Responses and a Prolonged Survival Tail in Advanced Hepatocellular Carcinoma with Portal Vein Invasion Treated with Y90 Radioembolization. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 1423-1424.	0.9	3
60	Immunotherapy in gastrointestinal cancer: The current scenario and future perspectives. <i>Cancer Treatment Reviews</i> , 2020, 88, 102030.	3.4	44
61	Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment. <i>Gene Expression</i> , 2020, 20, 53-65.	0.5	65
62	&lt;p&gt;Ramucirumab, A Second-Line Option For Patients With Hepatocellular Carcinoma: A Review Of The Evidence&lt;/p&gt;. <i>Cancer Management and Research</i> , 2020, Volume 12, 3721-3729.	0.9	15
63	Systemic therapy in advanced-stage hepatocellular carcinoma. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 212-217.	0.3	1
64	Recent Advances in Immunotherapy for Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 775.	1.7	70
65	Regorafenib Versus Nivolumab After Sorafenib Failure: Realâ€World Data in Patients With Hepatocellular Carcinoma. <i>Hepatology Communications</i> , 2020, 4, 1073-1086.	2.0	28
66	A meta-analysis comparing responses of Asian versus non-Asian cancer patients to PD-1 and PD-L1 inhibitor-based therapy. <i>Oncolmmunology</i> , 2020, 9, 1781333.	2.1	34
67	<p>Profile of Cabozantinib for the Treatment of Hepatocellular Carcinoma: Patient Selection and Special Considerations</p>. <i>Journal of Hepatocellular Carcinoma</i> , 2020, Volume 7, 91-99.	1.8	7
68	The Unmet Needs of the Diagnosis, Staging, and Treatment of Gastrointestinal Tumors. <i>Seminars in Nuclear Medicine</i> , 2020, 50, 389-398.	2.5	5
69	Obesity and Cancer Treatment Outcomes: Interpreting the Complex Evidence. <i>Clinical Oncology</i> , 2020, 32, 591-608.	0.6	33
70	Using dual checkpoint blockade to treat fibrolamellar hepatocellular carcinoma. <i>Gut</i> , 2020, 69, 2056.1-2058.	6.1	10
71	Role of Molecular Biomarkers in Liver Transplantation for Hepatocellular Carcinoma. <i>Liver Transplantation</i> , 2020, 26, 823-831.	1.3	25
72	Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 72, 307-319.	1.8	310
73	Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 72, 320-341.	1.8	165
74	Molecular therapies for HCC: Looking outside the box. <i>Journal of Hepatology</i> , 2020, 72, 342-352.	1.8	250

#	ARTICLE	IF	CITATIONS
75	Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 1089.	1.7	119
76	IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. <i>Future Oncology</i> , 2020, 16, 975-989.	1.1	136
77	Immunotherapy in hepatocellular carcinoma. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 218-222.	0.3	1
78	Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2. <i>Liver International</i> , 2020, 40, 2008-2020.	1.9	26
79	Mouse Models of Oncoimmunology in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 5276-5286.	3.2	13
80	Immune checkpoint inhibitors: use them early, combined and instead of TACE?. <i>Gut</i> , 2020, 69, 1887-1888.	6.1	21
81	ATM Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate Cancer. <i>Cancer Research</i> , 2020, 80, 2094-2100.	0.4	71
82	The Crosstalk between Tumor Cells and the Microenvironment in Hepatocellular Carcinoma: The Role of Exosomal microRNAs and Their Clinical Implications. <i>Cancers</i> , 2020, 12, 823.	1.7	40
83	Systemic therapies in advanced hepatocellular carcinoma: How do older patients fare?. <i>European Journal of Surgical Oncology</i> , 2021, 47, 583-590.	0.5	7
84	Biology and Clinical Application of Regulatory RNAs in Hepatocellular Carcinoma. <i>Hepatology</i> , 2021, 73, 38-48.	3.6	20
85	Evolution of Systemic Therapy for Hepatocellular Carcinoma. <i>Hepatology</i> , 2021, 73, 150-157.	3.6	70
86	Local and Regional Therapies for Hepatocellular Carcinoma. <i>Hepatology</i> , 2021, 73, 137-149.	3.6	69
87	Hepatocellular carcinoma, novel therapies on the horizon. <i>Chinese Clinical Oncology</i> , 2021, 10, 12-12.	0.4	12
88	Liver Cancer Immunity. <i>Hepatology</i> , 2021, 73, 86-103.	3.6	52
89	Stereotactic radiotherapy for hepatocellular carcinoma: Expanding the multidisciplinary armamentarium. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 873-884.	1.4	16
90	FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 1836-1841.	3.2	102
91	Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2021, 74, 350-359.	1.8	122
92	Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups. <i>Gut</i> , 2021, 70, 204-214.	6.1	150

#	ARTICLE	IF	CITATIONS
93	It takes two to tango: breakthrough advanced hepatocellular carcinoma treatment that combines anti-angiogenesis and immune checkpoint blockade. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 1-4.	0.8	8
94	Morphology of tumor and nontumor tissue in liver resection specimens for hepatocellular carcinoma following nivolumab therapy. <i>Modern Pathology</i> , 2021, 34, 823-833.	2.9	6
95	Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial. <i>Clinical Cancer Research</i> , 2021, 27, 1003-1011.	3.2	334
96	The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma. <i>JAMA Oncology</i> , 2021, 7, 113.	3.4	213
97	Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib. <i>Clinical Cancer Research</i> , 2021, 27, 713-718.	3.2	27
98	Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1593-1603.	2.0	32
99	Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells. <i>Cellular and Molecular Immunology</i> , 2021, 18, 112-127.	4.8	159
100	A Performance Comparison of Commonly Used Assays to Detect RET Fusions. <i>Clinical Cancer Research</i> , 2021, 27, 1316-1328.	3.2	39
101	Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab. <i>Liver International</i> , 2021, 41, 598-607.	1.9	13
102	Systemic targeted and immunotherapy for advanced hepatocellular carcinoma. <i>American Journal of Health-System Pharmacy</i> , 2021, 78, 187-202.	0.5	9
103	Dual targeting of PD-L1 and PD-L2 by PCED1B-AS1 via sponging hsa-miR-194-5p induces immunosuppression in hepatocellular carcinoma. <i>Hepatology International</i> , 2021, 15, 444-458.	1.9	62
104	Hyperprogression in hepatocellular carcinoma: Illusion or reality?. <i>Journal of Hepatology</i> , 2021, 74, 269-271.	1.8	9
105	Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review. <i>Journal of the National Cancer Institute</i> , 2021, 113, 123-136.	3.0	28
106	Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma. <i>Cancer Treatment and Research Communications</i> , 2021, 27, 100328.	0.7	70
107	Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort. <i>Liver Cancer</i> , 2021, 10, 360-369.	4.2	25
108	Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study. <i>Liver Cancer</i> , 2021, 10, 107-114.	4.2	66
109	Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110180.	1.4	10
110	Perspectives in immunotherapy: meeting report from the "ImmunoTherapy Bridge" (December 4th-5th), Tj 1.8-1.8	1.8	103784314

#	ARTICLE	IF	CITATIONS
111	Optimizing the Combination of Immunotherapy and Trans-Arterial Locoregional Therapy for Stages B and C Hepatocellular Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 1499-1510.	0.7	3
112	Impaired Response to Immunotherapy in Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma?. <i>Liver Cancer</i> , 2021, 10, 289-295.	4.2	6
113	Systemic therapy of liver cancer. <i>Advances in Cancer Research</i> , 2021, 149, 257-294.	1.9	44
114	Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110311.	1.4	19
115	Immunotherapy in hepatocellular cancer. <i>Advances in Cancer Research</i> , 2021, 149, 295-320.	1.9	0
116	The evolving landscape of systemic treatment for advanced hepatocellular carcinoma and biliary tract cancer. <i>Cancer Treatment and Research Communications</i> , 2021, 27, 100360.	0.7	4
117	Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110027.	1.4	91
118	Application of ASCO Value Framework to Treatment Advances in Hepatocellular Carcinoma. <i>JCO Oncology Practice</i> , 2021, 17, OP.20.00558.	1.4	4
119	Cost-Effectiveness Analysis of Selective Internal Radiotherapy With Yttrium-90 Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma. <i>JCO Oncology Practice</i> , 2021, 17, e266-e277.	1.4	12
120	The Evolving Landscape of Checkpoint Inhibitor Combination Therapy in the Treatment of Advanced Hepatocellular Carcinoma. <i>Targeted Oncology</i> , 2021, 16, 153-163.	1.7	5
121	The Role of IGF/IGF-1R Signaling in Hepatocellular Carcinomas: Stemness-Related Properties and Drug Resistance. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1931.	1.8	31
122	PD-L1 as a biomarker of response to immune-checkpoint inhibitors. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 345-362.	12.5	646
123	Clinical Characterisation and Management of the Main Treatment-Induced Toxicities in Patients with Hepatocellular Carcinoma and Cirrhosis. <i>Cancers</i> , 2021, 13, 584.	1.7	6
124	Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice. <i>European Journal of Radiology</i> , 2021, 135, 109484.	1.2	20
125	Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors. , 2021, 9, e001945.		74
126	First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. <i>Cancers</i> , 2021, 13, 931.	1.7	26
127	Management of Non-Colorectal Digestive Cancers with Microsatellite Instability. <i>Cancers</i> , 2021, 13, 651.	1.7	7
128	Emerging Role of Immune Therapy in HCC. <i>Digestive Disease Interventions</i> , 2021, 05, 277-282.	0.3	0



#	ARTICLE	IF	CITATIONS
129	Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 652172.	2.2	21
130	Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial. , 2021, 9, e002191.		38
131	Comparison of Efficacy of Systemic Therapies in Advanced Hepatocellular Carcinoma: Updated Systematic Review and Frequentist Network Meta-Analysis of Randomized Controlled Trials. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 145-154.	1.8	12
132	Hepatocellular carcinoma: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCG, GERCOR, UNICANCER, SFGC, SFED, SFRO, AFEF, SIAD, SFR/FRI). <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101590.	0.7	17
133	Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis. <i>Biomarker Research</i> , 2021, 9, 19.	2.8	43
134	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. <i>Nature</i> , 2021, 592, 450-456.	13.7	649
135	Recent Progress in Systemic Therapy for Hepatocellular Cancer (HCC). <i>Current Treatment Options in Gastroenterology</i> , 2021, 19, 351-368.	0.3	6
136	Outcome of Immune Checkpoint Inhibitor and Molecular Target Agent Combination for Advanced Hepatocellular Carcinoma: Beyond Sorafenib Era. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2021, 77, 145-147.	0.2	0
137	Beyond First-Line Immune Checkpoint Inhibitor Therapy in Patients With Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 652007.	2.2	7
138	The Efficacy and Safety of Programmed Death-1 and Programmed Death Ligand 1 Inhibitors for the Treatment of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 626984.	1.3	12
139	Current and future perspective on targeted agents and immunotherapies in hepatocellular carcinoma. <i>Minerva Gastroenterology</i> , 2021, 67, .	0.3	7
140	Immunomodulatory Treatment Strategies of Hepatocellular Carcinoma: From Checkpoint Inhibitors Now to an Integrated Approach in the Future. <i>Cancers</i> , 2021, 13, 1558.	1.7	8
141	Nivolumab + Ipilimumab for patients with hepatocellular carcinoma previously treated with Sorafenib. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 589-598.	1.4	17
142	Toward a new landscape for the mechanism of immunosuppression in hepatocellular carcinoma. <i>Hepatology International</i> , 2021, 15, 287-289.	1.9	2
143	The Role of Cabozantinib as a Therapeutic Option for Hepatocellular Carcinoma: Current Landscape and Future Challenges. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 177-191.	1.8	9
145	Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma. <i>JAMA Network Open</i> , 2021, 4, e214846.	2.8	42
146	Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression. <i>British Journal of Cancer</i> , 2021, 125, 190-199.	2.9	26
147	Immunotherapy Updates in Advanced Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 2164.	1.7	14

#	ARTICLE	IF	CITATIONS
148	A Comparison of Lenvatinib versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma: Selection Criteria to Guide Physician's Choice in a New Therapeutic Scenario. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 241-251.	1.8	12
149	Frontiers of therapy for hepatocellular carcinoma. <i>Abdominal Radiology</i> , 2021, 46, 3648-3659.	1.0	16
150	Advances in immunotherapy for hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 525-543.	8.2	609
151	Natural Killer Cells and Regulatory T Cells Cross Talk in Hepatocellular Carcinoma: Exploring Therapeutic Options for the Next Decade. <i>Frontiers in Immunology</i> , 2021, 12, 643310.	2.2	27
152	Comparison of HBV reactivation between patients with high HBV-DNA and low HBV-DNA loads undergoing PD-1 inhibitor and concurrent antiviral prophylaxis. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3207-3216.	2.0	21
153	The Current Landscape of Clinical Trials for Systemic Treatment of HCC. <i>Cancers</i> , 2021, 13, 1962.	1.7	40
154	NAFLD-Associated HCC: Progress and Opportunities. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 223-239.	1.8	33
155	Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial. <i>Clinical Cancer Research</i> , 2021, 27, 3567-3575.	3.2	53
156	Therapies for hepatocellular carcinoma: overview, clinical indications, and comparative outcome evaluation. Part two: noncurative intention. <i>Abdominal Radiology</i> , 2021, 46, 3540-3548.	1.0	3
157	The evolving treatment paradigm of advanced hepatocellular carcinoma: putting all the pieces back together. <i>Current Opinion in Oncology</i> , 2021, 33, 386-394.	1.1	13
158	Immune Checkpoint Inhibitor Associated Hepatotoxicity in Primary Liver Cancer Versus Other Cancers: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 650292.	1.3	22
159	The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong—A Territory-Wide Cohort Study. <i>Cancers</i> , 2021, 13, 2002.	1.7	8
160	Recent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC. <i>Cancers</i> , 2021, 13, 1949.	1.7	31
161	Comparative Efficacy of Atezolizumab plus Bevacizumab and Other Treatment Options for Patients with Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis. <i>Liver Cancer</i> , 2021, 10, 240-248.	4.2	39
162	Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib/II Study. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 1873-1882.	2.0	20
164	Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 172.	3.5	104
165	Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure. <i>Frontiers in Oncology</i> , 2021, 11, 683341.	1.3	13
166	Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression. <i>British Journal of Cancer</i> , 2021, 125, 200-208.	2.9	22

#	ARTICLE	IF	CITATIONS
167	Kinetics of the neutrophil-lymphocyte ratio during PD-1 inhibition as a prognostic factor in advanced hepatocellular carcinoma. <i>Liver International</i> , 2021, 41, 2189-2199.	1.9	26
168	The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment. <i>Vaccines</i> , 2021, 9, 532.	2.1	65
169	Hepatocellular Carcinoma: An Overview of the Changing Landscape of Treatment Options. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 387-401.	1.8	62
170	The therapeutic landscape of hepatocellular carcinoma. <i>Med</i> , 2021, 2, 505-552.	2.2	20
171	Role of modern radiotherapy in managing patients with hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2021, 27, 2434-2457.	1.4	18
172	Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5801.	1.8	182
173	Systemic Therapy for Hepatocellular Carcinoma. <i>Clinical Liver Disease</i> , 2021, 17, 337-340.	1.0	5
174	Tumor Immunity and Immunotherapy for HPV-Related Cancers. <i>Cancer Discovery</i> , 2021, 11, 1896-1912.	7.7	71
175	Safety of PD-1/PD-L1 Inhibitors Combined With Palliative Radiotherapy and Anti-Angiogenic Therapy in Advanced Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 686621.	1.3	28
176	Immunotherapy for GI Cancers. <i>Advances in Oncology</i> , 2021, 1, 283-295.	0.1	0
177	Combination Immunotherapy for Hepatocellular Carcinoma: Where Are We Currently?. <i>Seminars in Liver Disease</i> , 2021, 41, 136-141.	1.8	10
178	Advances in systemic therapy for the first-line treatment of unresectable HCC. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 621-628.	1.1	11
179	Back to the basics: How the preclinical rationale shapes the immunotherapy landscape for hepatocellular carcinoma. <i>Liver Cancer International</i> , 2021, 2, 5-6.	0.2	1
180	Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. <i>Medicina Clínica (English Edition)</i> , 2021, 156, 463.e1-463.e30.	0.1	16
181	Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials. <i>World Journal of Gastroenterology</i> , 2021, 27, 2415-2433.	1.4	16
182	Cellular based treatment modalities for unresectable hepatocellular carcinoma. <i>World Journal of Clinical Oncology</i> , 2021, 12, 290-308.	0.9	4
183	Favorable response to second-line atezolizumab and bevacizumab following progression on nivolumab in advanced hepatocellular carcinoma. <i>Medicine (United States)</i> , 2021, 100, e26471.	0.4	5
184	A Phase 2 Study of Camrelizumab for Advanced Hepatocellular Carcinoma: Two-Year Outcomes and Continued Treatment beyond First RECIST-Defined Progression. <i>Liver Cancer</i> , 2021, 10, 500-509.	4.2	9

#	ARTICLE	IF	CITATIONS
185	Potential experimental immune checkpoint inhibitors for the treatment of cancer of the liver. Expert Opinion on Investigational Drugs, 2021, 30, 827-835.	1.9	3
186	Exploring liver cancer biology through functional genetic screens. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 690-704.	8.2	31
187	Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology. Liver International, 2021, 41, 2759-2767.	1.9	5
188	Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges. Cancer Communications, 2021, 41, 830-850.	3.7	42
189	Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait. Immunotherapy, 2021, 13, 637-644.	1.0	63
190	Atezolizumab and bevacizumab for hepatocellular carcinoma: mechanism, pharmacokinetics and future treatment strategies. Future Oncology, 2021, 17, 2243-2256.	1.1	36
191	Clinical Trials of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Journal of Clinical Medicine, 2021, 10, 2662.	1.0	13
192	MAPK/ERK Signaling Pathway in Hepatocellular Carcinoma. Cancers, 2021, 13, 3026.	1.7	104
193	<sc>FDA</sc> Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib. Oncologist, 2021, 26, 797-806.	1.9	61
194	Portal hypertension and hepatocellular carcinoma: Des liaisons dangereuses. Liver International, 2021, 41, 1734-1743.	1.9	31
195	The TGF- $\beta$ Pathway: A Pharmacological Target in Hepatocellular Carcinoma?. Cancers, 2021, 13, 3248.	1.7	37
196	Real-world Experience of Olaparib Treatment in Patients with Ovarian Cancer: A Chinese Multicenter Study. Molecular Cancer Therapeutics, 2021, 20, 1735-1742.	1.9	8
197	Prospects and Challenges for T Cell-Based Therapies of HCC. Cells, 2021, 10, 1651.	1.8	13
198	Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Annals of Oncology, 2021, 32, 801-805.	0.6	235
199	Treatment strategies for hepatocellular carcinoma with extrahepatic metastasis. World Journal of Clinical Cases, 2021, 9, 5754-5768.	0.3	9
200	Cabozantinib: An evolving therapy for hepatocellular carcinoma. Cancer Treatment Reviews, 2021, 98, 102221.	3.4	43
201	Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors and Applicability of First-Line Atezolizumab/Bevacizumab in a Real-Life Setting. Journal of Clinical Medicine, 2021, 10, 3201.	1.0	13
202	Systemic therapy for hepatocellular carcinoma: current status and future perspectives. Japanese Journal of Clinical Oncology, 2021, 51, 1363-1371.	0.6	3

#	ARTICLE	IF	CITATIONS
203	Clinical Activity and Safety of Penpulimab (Anti-PD-1) With Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib/II Trial (AK105-203). <i>Frontiers in Oncology</i> , 2021, 11, 684867.	1.3	35
204	Anti-angiogenesis Revisited: Combination with Immunotherapy in Solid Tumors. <i>Current Oncology Reports</i> , 2021, 23, 100.	1.8	26
205	A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 4994-5003.	3.2	24
206	Hepatocellular Carcinoma Immunotherapy and the Potential Influence of Gut Microbiome. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7800.	1.8	26
207	Recent advances in immunotherapy for hepatocellular carcinoma. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2021, 20, 511-520.	0.6	29
208	Evolution of systemic treatment for advanced hepatocellular carcinoma. <i>Kaohsiung Journal of Medical Sciences</i> , 2021, 37, 643-653.	0.8	11
209	Evolving therapeutic strategies for advanced hepatocellular carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1-12.	0.9	2
210	Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2â€³ study. <i>Lancet Oncology</i> , The, 2021, 22, 977-990.	5.1	459
211	Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response. , 2021, 9, e003132.		17
212	Systemic therapy for hepatocellular carcinoma: New agents and therapeutic hierarchy. <i>Journal of the Formosan Medical Association</i> , 2021, , .	0.8	0
213	Cancer and hepatic steatosis. <i>ESMO Open</i> , 2021, 6, 100185.	2.0	9
214	PD-1 Blockade for Hepatocellular Carcinoma: Current Research and Future Prospects. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 887-897.	1.8	17
215	First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 1245-1251.	1.4	75
216	Lack of response to immunotherapy in non-alcoholic steatohepatitis related hepatocellular carcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 522-525.	0.7	9
217	Are we ready for patient-reported outcomes in hepatocellular carcinoma?. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 602-603.	3.7	0
218	Treatment of Advanced Hepatocellular Carcinoma. , 0, , .		0
219	Efficacy and Safety Results from a Phase 2, Randomized, Double-Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular Carcinoma. <i>Clinical Drug Investigation</i> , 2021, 41, 795-808.	1.1	4
220	Role of Virus-Related Chronic Inflammation and Mechanisms of Cancer Immune-Suppression in Pathogenesis and Progression of Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 4387.	1.7	15

#	ARTICLE	IF	CITATIONS
221	Emerging treatment modalities for systemic therapy in hepatocellular carcinoma. Biomarker Research, 2021, 9, 64.	2.8	13
222	Treatments of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: Current Status and Controversy. Journal of Clinical and Translational Hepatology, 2022, 10, 147-158.	0.7	21
223	Non-surgical management of advanced hepatocellular carcinoma: A systematic review by Cancer Care Ontario. Canadian Liver Journal, 2021, 4, 257-274.	0.3	4
224	Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma. Expert Review of Anticancer Therapy, 2021, 21, 927-939.	1.1	9
225	Genetic Heterogeneity, Therapeutic Hurdle Confronting Sorafenib and Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Cancers, 2021, 13, 4343.	1.7	8
226	Application of Immunotherapy in Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 699060.	1.3	8
227	Systematic literature review of trials assessing recommended systemic treatments in hepatocellular carcinoma. Hepatic Oncology, 2022, 9, HEP41.	4.2	2
228	Immunotherapy in Hepatocellular Carcinoma. Current Treatment Options in Oncology, 2021, 22, 87.	1.3	25
229	PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials?. Expert Opinion on Investigational Drugs, 2022, 31, 415-423.	1.9	78
230	A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by 90Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 1129-1145.	1.8	5
232	Immune aspects of hepatocellular carcinoma: From immune markers for early detection to immunotherapy. World Journal of Gastrointestinal Oncology, 2021, 13, 1132-1143.	0.8	2
233	Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation. Cancers, 2021, 13, 4882.	1.7	15
234	Lenvatinib with or without immune checkpoint inhibitors for patients with unresectable hepatocellular carcinoma in real-world clinical practice. Cancer Immunology, Immunotherapy, 2022, 71, 1063-1074.	2.0	26
235	Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy.. , 2021, 9, e003311.		66
237	Second-Line Treatment Options for Hepatocellular Carcinoma: Current Landscape and Future Direction. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 1147-1158.	1.8	8
238	How Immunotherapy Has Changed the Continuum of Care in Hepatocellular Carcinoma. Cancers, 2021, 13, 4719.	1.7	7
239	Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy. Frontiers in Oncology, 2021, 11, 716844.	1.3	12
240	Gadoxetic acid uptake as a molecular imaging biomarker for sorafenib resistance in patients with hepatocellular carcinoma: a post hoc analysis of the SORAMIC trial. Journal of Cancer Research and Clinical Oncology, 2021, , 1.	1.2	3

#	ARTICLE	IF	CITATIONS
241	Sintilimab plus IBI305 for hepatocellular carcinoma. <i>Lancet Oncology</i> , The, 2021, 22, e386.	5.1	0
242	Predictive biomarkers for systemic therapy of hepatocellular carcinoma. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 1147-1164.	1.5	17
243	NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options. <i>Journal of Hepatology</i> , 2022, 76, 446-457.	1.8	121
244	Lung and lymph node metastases from hepatocellular carcinoma: Comparison of pathological aspects. <i>Liver International</i> , 2022, 42, 199-209.	1.9	19
245	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. , 2021, 9, e002794.		43
246	Infiltrative hepatocellular carcinoma with multiple lung metastasis completely cured using nivolumab: a case report. <i>Journal of Liver Cancer</i> , 2021, 21, 169-176.	0.3	1
247	Paradigm shift in the treatment options of hepatocellular carcinoma. <i>Liver International</i> , 2022, 42, 2067-2079.	1.9	19
248	Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 3002-3011.	0.8	171
250	Horizons of development of immunotherapy for malignant liver tumors. <i>Eksperimental'naya i Klinicheskaya Gastroenterologiya</i> , 2021, , 81-89.	0.1	0
251	Systemic Therapy in Hepatocellular Carcinoma. , 0, , .		0
252	The Progress in the Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus. <i>Frontiers in Oncology</i> , 2021, 11, 635731.	1.3	26
253	Advances in immune checkpoint inhibitors for hepatocellular carcinoma. <i>Journal of Liver Cancer</i> , 2021, 21, 139-145.	0.3	3
254	Systemic therapy for advanced hepatocellular carcinoma: consideration for selecting second-line treatment. <i>Journal of Liver Cancer</i> , 2021, 21, 124-138.	0.3	2
255	Systemic treatment of hepatocellular carcinoma: An EASL position paper. <i>Journal of Hepatology</i> , 2021, 75, 960-974.	1.8	217
256	ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma. <i>JHEP Reports</i> , 2021, 3, 100347.	2.6	57
257	Decision making in systemic therapy of hepatocellular carcinoma: Should we pay attention to disease aetiology?. <i>Journal of Hepatology</i> , 2021, 75, 763-764.	1.8	1
258	Viral infections and the efficacy of PD-(L)1 inhibitors in virus-related cancers: Head and neck squamous cell carcinoma and hepatocellular carcinoma. <i>International Immunopharmacology</i> , 2021, 100, 108128.	1.7	13
259	Potential predictors for survival in hepatocellular carcinoma patients treated with immune checkpoint inhibitors: A meta-analysis. <i>International Immunopharmacology</i> , 2021, 100, 108135.	1.7	3

#	ARTICLE	IF	CITATIONS
260	Immunotherapy and chimeric antigen receptor T-cell therapy in hepatocellular carcinoma. <i>Chinese Clinical Oncology</i> , 2021, 10, 11-11.	0.4	8
261	A Phase II Trial of Y90-Resin Microspheres Radioembolization Followed by Nivolumab in Advanced Hepatocellular Carcinomaâ€” CA 209-678. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
262	Emerging immune checkpoint inhibitors for the treatment of hepatocellular carcinoma. <i>Expert Opinion on Emerging Drugs</i> , 2021, 26, 39-52.	1.0	9
263	The Growing Skyline of Advanced Hepatocellular Carcinoma Treatment: A Review. <i>Pharmaceuticals</i> , 2021, 14, 43.	1.7	8
264	Hepatocellular carcinoma. <i>Nature Reviews Disease Primers</i> , 2021, 7, 6.	18.1	2,757
265	Immune Checkpoint Inhibitors in the Treatment of HCC. <i>Frontiers in Oncology</i> , 2020, 10, 601240.	1.3	77
266	Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2). <i>Liver Cancer</i> , 2021, 10, 451-460.	4.2	5
267	Immunotherapies in clinical development for biliary tract cancer. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 351-363.	1.9	28
268	A clinical trial with valproic acid and hydralazine in combination with gemcitabine and cisplatin followed by doxorubicin and dacarbazine for advanced hepatocellular carcinoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, 18, 19-27.	0.7	2
269	Cancer of unknown primary. <i>BMJ, The</i> , 2020, 371, m4050.	3.0	38
270	Ramucirumab for patients with intermediate-stage hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): Pooled results from two phase III studies (REACH and REACH-2).. <i>Journal of Clinical Oncology</i> , 2020, 38, 549-549.	0.8	4
271	Hepatocellular carcinoma: recent advances and emerging medical therapies. <i>F1000Research</i> , 2020, 9, 620.	0.8	41
272	Camrelizumabâ€™”targeting a novel PD-1 epitope to treat hepatocellular carcinoma. <i>Annals of Translational Medicine</i> , 2020, 8, 1614-1614.	0.7	2
273	Current Translational and Clinical Challenges in Advanced Hepatocellular Carcinoma. <i>Current Medicinal Chemistry</i> , 2020, 27, 4789-4805.	1.2	6
274	Immune Phenotype and Immune Checkpoint Inhibitors for the Treatment of Human Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 1274.	1.7	27
275	Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 90.	1.7	21
276	Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview. <i>Pharmaceuticals</i> , 2021, 14, 3.	1.7	16
277	Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma: A Literature Review and Treatment Perspectives. <i>Pharmaceuticals</i> , 2021, 14, 28.	1.7	17



#	ARTICLE	IF	CITATIONS
278	Current Status and Future Direction of Immunotherapy in Hepatocellular Carcinoma: What Do the Data Suggest?. <i>Immune Network</i> , 2020, 20, e11.	1.6	42
279	Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 541-565.	2.3	477
280	Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects. <i>Frontiers in Immunology</i> , 2021, 12, 765101.	2.2	63
281	Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma. <i>Immunotherapy</i> , 2021, 13, 1395-1405.	1.0	35
282	Camrelizumab Plus Sorafenib Versus Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 694409.	1.3	10
283	Thermal ablation and immunotherapy for hepatocellular carcinoma: Recent advances and future directions. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 1397-1411.	0.8	9
284	Cure the Incurable? Recent Breakthroughs in Immune Checkpoint Blockade for Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 5295.	1.7	9
285	Targeting CDC7 potentiates ATR-Chk1 signaling inhibition through induction of DNA replication stress in liver cancer. <i>Genome Medicine</i> , 2021, 13, 166.	3.6	19
286	Research progress regarding programmed cell death 1/programmed cell death ligand 1 inhibitors combined with targeted therapy for treating hepatocellular carcinoma. <i>World Journal of Gastrointestinal Surgery</i> , 2021, 13, 1136-1148.	0.8	2
287	The Immunology of Hepatocellular Carcinoma. <i>Vaccines</i> , 2021, 9, 1184.	2.1	41
288	Advances in Pharmacotherapy of Hepatocellular Carcinoma: A State-of-the-Art Review. <i>Digestive Diseases</i> , 2022, 40, 565-580.	0.8	4
289	Safety of ramucirumab treatment in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein. <i>Expert Opinion on Drug Safety</i> , 2021, , 1-10.	1.0	1
290	Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 1025-1035.	3.7	56
291	Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFTY score. <i>Journal of Hepatology</i> , 2022, 76, 353-363.	1.8	132
292	Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma. <i>JGH Open</i> , 2021, 5, 1275-1283.	0.7	12
293	Immunotherapy after liver transplantation: Where are we now?. <i>World Journal of Gastrointestinal Surgery</i> , 2021, 13, 1267-1278.	0.8	20
294	Hepatotoxicity of systemic therapies for unresectable hepatocellular carcinoma. <i>Liver Cancer International</i> , 0, , .	0.2	3
295	Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges. <i>Frontiers in Oncology</i> , 2021, 11, 737497.	1.3	22

#	ARTICLE	IF	CITATIONS
296	Serum LAG-3 Predicts Outcome and Treatment Response in Hepatocellular Carcinoma Patients With Transarterial Chemoembolization. <i>Frontiers in Immunology</i> , 2021, 12, 754961.	2.2	16
297	Immunotherapy after liver transplantation: Where are we now?. <i>World Journal of Gastrointestinal Surgery</i> , 2021, 13, 1266-1277.	0.8	0
298	Therapeutic effectiveness and safety of sintilimab-dominated triple therapy in unresectable hepatocellular carcinoma. <i>Scientific Reports</i> , 2021, 11, 19711.	1.6	9
299	Combination therapy with PD-1 blockade and radiofrequency ablation for recurrent hepatocellular carcinoma: a propensity score matching analysis. <i>International Journal of Hyperthermia</i> , 2021, 38, 1519-1528.	1.1	21
300	Exploring microsatellite instability in patients with advanced hepatocellular carcinoma and its tumor microenvironment. <i>JGH Open</i> , 2021, 5, 1266-1274.	0.7	9
301	Second-line treatment of hepatocellular carcinoma: from theory to practical issues. <i>Meditinskiy Sovet</i> , 2019, , 30-36.	0.1	2
302	Response Stratification in the First-Line Combined Immunotherapy of Hepatocellular Carcinoma at Genomic, Transcriptional and Immune Repertoire Levels. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 1281-1295.	1.8	10
303	Current role of systemic therapy in transarterial chemotherapy refractory hepatocellular carcinoma patients. <i>International Journal of Gastrointestinal Intervention</i> , 2021, 10, 183-188.	0.1	1
304	Changing the Treatment Paradigm for Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab Combination Therapy. <i>Cancers</i> , 2021, 13, 5475.	1.7	10
307	Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma. <i>Saudi Journal of Gastroenterology</i> , 2020, 26, 1.	0.5	13
308	Nivolumab for Advanced Hepatocellular Carcinoma with Multiple Lung Metastases after Sorafenib Failure. <i>Journal of Liver Cancer</i> , 2020, 20, 72-77.	0.3	1
309	Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma. <i>Biomedicines</i> , 2021, 9, 1639.	1.4	84
310	Current Perspectives on the Immunosuppressive Niche and Role of Fibrosis in Hepatocellular Carcinoma and the Development of Antitumor Immunity. <i>Journal of Histochemistry and Cytochemistry</i> , 2022, 70, 53-81.	1.3	6
311	Interplay between Cellular and Non-Cellular Components of the Tumour Microenvironment in Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 5586.	1.7	13
312	Clinical research progress of immune checkpoint inhibitors in treatment of primary liver cancer. <i>World Chinese Journal of Digestology</i> , 2020, 28, 605-616.	0.0	0
313	Early Experience of Oncolytic Virus Injection Combined with Sorafenib in a Patient with Advanced Hepatocellular Carcinoma and Portal Vein Thrombosis. <i>Journal of Liver Cancer</i> , 2020, 20, 177-182.	0.3	1
314	Imaging and Radiomics of Immuno-oncology of Primary and Secondary Gastrointestinal Malignancies. <i>Digestive Disease Interventions</i> , 2020, 04, 373-381.	0.3	0
315	Systemic Therapy for Hepatocellular Carcinoma: Advances and Hopes. <i>Current Gene Therapy</i> , 2020, 20, 84-99.	0.9	11

#	ARTICLE	IF	CITATIONS
316	Hypoxia as a driver of resistance to immunotherapy. <i>Drug Resistance Updates</i> , 2021, 59, 100787.	6.5	94
317	Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 783236.	2.2	66
318	Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors. <i>Cancers</i> , 2021, 13, 5665.	1.7	5
319	Lenvatinib Plus Immune Checkpoint Inhibitors Improve Survival in Advanced Hepatocellular Carcinoma: A Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 751159.	1.3	16
320	Immunotherapies for hepatocellular carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 151-172.	12.5	643
321	Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib. <i>ESMO Open</i> , 2021, 6, 100330.	2.0	25
322	Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110638.	0.8	10
323	To "or not to", that is the question: A narrative review on P value. <i>Cancer Research Statistics and Treatment</i> , 2021, 4, 756.	0.1	6
324	Success is not final, failure is not fatal: The changing landscape of systemic therapy for advanced hepatocellular carcinoma. <i>Journal of Cancer Research and Practice</i> , 2021, 8, 127.	0.2	2
325	HHLA2 Immune Checkpoint Is a Novel Prognostic Predictor in Hepatocellular Carcinoma. <i>American Journal of Clinical Pathology</i> , 2022, 158, 62-69.	0.4	4
326	Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
327	Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study. <i>BMC Cancer</i> , 2022, 22, 55.	1.1	14
328	Bayesian interpretation of immunotherapy trials with dynamic treatment effects. <i>European Journal of Cancer</i> , 2022, 161, 79-89.	1.3	3
329	Immunotherapy in older patients with hepatocellular carcinoma. <i>European Journal of Cancer</i> , 2022, 162, 76-98.	1.3	8
330	Combining immune checkpoint inhibitor with lenvatinib prolongs survival than lenvatinib alone in sorafenib-experienced hepatocellular carcinoma patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 213-219.	0.8	10
331	Tivozanib for hepatocellular carcinoma: not likely a new option. <i>Annals of Translational Medicine</i> , 2020, 8, 1337-1337.	0.7	0
332	Non-alcoholic fatty liver disease and hepatocellular carcinoma: Clinical challenges of an intriguing link. <i>World Journal of Gastroenterology</i> , 2022, 28, 310-331.	1.4	29
333	Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 401-413.	1.9	9

#	ARTICLE	IF	CITATIONS
334	Hepatocellular Carcinoma: Molecular Pathogenesis and Therapeutic Advances. <i>Cancers</i> , 2022, 14, 621.	1.7	34
335	Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol. <i>Future Oncology</i> , 2022, 18, 1423-1435.	1.1	14
336	Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial. <i>Genome Medicine</i> , 2022, 14, 1.	3.6	68
337	Immunotherapy in liver transplantation for hepatocellular carcinoma: Pros and cons. <i>World Journal of Gastrointestinal Oncology</i> , 2022, 14, 163-180.	0.8	12
338	Recent advances in systemic therapy for hepatocellular carcinoma. <i>Biomarker Research</i> , 2022, 10, 3.	2.8	94
339	Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations. <i>Journal of Clinical Oncology</i> , 2022, 40, 611-625.	0.8	242
340	Hepatic interferon regulatory factor 8 expression suppresses hepatocellular carcinoma progression and enhances the response to anti-“programmed cell death protein” therapy. <i>Hepatology</i> , 2022, 76, 1602-1616.	3.6	18
341	Precision Medicine for Hepatocellular Carcinoma: Clinical Perspective. <i>Journal of Personalized Medicine</i> , 2022, 12, 149.	1.1	14
343	Ferroptosis Regulator Modification Patterns and Tumor Microenvironment Immune Infiltration Characterization in Hepatocellular Carcinoma. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 807502.	1.6	4
344	Efficacy of targeted therapies for oncogene-driven lung cancer in early single-arm versus late phase randomized clinical trials: A comparative analysis. <i>Cancer Treatment Reviews</i> , 2022, 104, 102354.	3.4	2
345	Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?. <i>Future Oncology</i> , 2022, , .	1.1	4
347	Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma. , 2022, 10, e003534.		56
348	T-Cell Subsets as Potential Biomarkers for Hepatobiliary Cancers and Selection of Immunotherapy Regimens as a Treatment Strategy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 203-214.	2.3	1
349	Advances in understanding role of gut microbiota in immunotherapy for hepatocellular carcinoma. <i>World Chinese Journal of Digestology</i> , 2022, 30, 147-151.	0.0	0
350	Immunotherapies for hepatocellular carcinoma. <i>Cancer Medicine</i> , 2022, 11, 571-591.	1.3	29
351	Camrelizumab: an investigational agent for hepatocellular carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 337-346.	1.9	6
352	The Role of Immune Checkpoint Blockade in the Hepatocellular Carcinoma: A Review of Clinical Trials. <i>Frontiers in Oncology</i> , 2021, 11, 801379.	1.3	21
353	Immunotherapy in GI Cancers: Hepatocellular Carcinoma: Perspective. , 2022, , 177-183.		0

#	ARTICLE	IF	CITATIONS
354	Updates on the staging and treatment of hepatocellular carcinoma. , 2022, , 307-319.		0
355	PD-1 targeted immunotherapy for advanced hepatocellular carcinoma: current utilization and outcomes in the USA. <i>Future Oncology</i> , 2022, 18, 1691-1703.	1.1	4
356	The dual checkpoint blockade in unresectable hepatocellular carcinoma: opportunities emerging in clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 425-435.	1.9	3
357	Serum Concentration of CD137 and Tumor Infiltration by M1 Macrophages Predict the Response to Sintilimab plus Bevacizumab Biosimilar in Advanced Hepatocellular Carcinoma Patients. <i>Clinical Cancer Research</i> , 2022, 28, 3499-3508.	3.2	32
358	Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook. <i>Journal of Hepatocellular Carcinoma</i> , 2022, Volume 9, 233-263.	1.8	27
360	Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma. <i>BMC Cancer</i> , 2022, 22, 270.	1.1	23
361	Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View. <i>Cancers</i> , 2022, 14, 1760.	1.7	20
362	Immunotherapy and Transarterial therapy of <scp>HCC</scp>: What the interventional radiologist needs to know about the changing landscape of <scp>HCC</scp> treatment?. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2022, 66, 478-482.	0.9	10
363	Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study. <i>Frontiers in Immunology</i> , 2022, 13, 848387.	2.2	66
364	Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma. <i>Expert Review of Molecular Diagnostics</i> , 2022, 22, 253-264.	1.5	20
365	AGA Technical Review on Systemic Therapies for Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2022, 162, 937-951.	0.6	5
366	Safety and Efficacy of Sorafenib and Lenvatinib in Patients Who Underwent Surgery or Whole-Brain Radiotherapy for Brain Metastasis of Hepatocellular Carcinoma. <i>Journal of Clinical Medicine</i> , 2022, 11, 1536.	1.0	0
367	Efficacy and Safety of Atezolizumab and Bevacizumab in the Real-World Treatment of Advanced Hepatocellular Carcinoma: Experience from Four Tertiary Centers. <i>Cancers</i> , 2022, 14, 1722.	1.7	26
368	AGA Clinical Practice Guideline on Systemic Therapy for Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2022, 162, 920-934.	0.6	81
369	Rapidly Evolving Landscape and Future Horizons in Hepatocellular Carcinoma in the Era of Immuno-Oncology. <i>Frontiers in Oncology</i> , 2022, 12, 821903.	1.3	2
370	Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study. <i>Cancers</i> , 2022, 14, 1747.	1.7	36
371	The Treatment Landscape of Advanced Hepatocellular Carcinoma. <i>Current Oncology Reports</i> , 2022, 24, 917-927.	1.8	21
372	Tumor-immune Co-evolution in Hepatocellular Carcinoma and Its Implication for Immunotherapy Resistance. , 2022, , .		1

#	ARTICLE	IF	CITATIONS
373	Is hepatocellular carcinoma complicated with portal vein tumor thrombosis potentially curable by radiotherapy in the form of stereotactic body radiation therapy?. <i>International Journal of Radiation Biology</i> , 2022, 98, 1495-1509.	1.0	1
374	Prognostic value of PD-L1 expression combined with hypoxia-associated immunosuppression in hepatocellular carcinoma. <i>Biomarkers in Medicine</i> , 2022, 16, 435-448.	0.6	0
375	Immune checkpoint inhibitors for hepatocellular carcinoma – A game changer in treatment landscape. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 1371-1383.	0.8	3
376	Emerging immunotherapy for HCC: A guide for hepatologists. <i>Hepatology</i> , 2022, 75, 1604-1626.	3.6	97
377	Cardiovascular toxicity following immune checkpoint inhibitors: A systematic review and meta-analysis. <i>Translational Oncology</i> , 2022, 19, 101383.	1.7	4
378	Programmed Cell Death 1 and Hepatocellular Carcinoma: An Epochal Story. <i>Journal of Gastrointestinal Cancer</i> , 2021, 52, 1217-1222.	0.6	3
379	The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 186.	1.7	44
380	Immune System Disorders, Cancer and Viral Infections: A New Treatment Opportunity for the Immune Checkpoint Inhibitors. <i>Life</i> , 2021, 11, 1400.	1.1	1
381	Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors. <i>Frontiers in Immunology</i> , 2021, 12, 794099.	2.2	34
382	Combined Stereotactic Body Radiotherapy and Immunotherapy Versus Transarterial Chemoembolization in Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 798832.	1.3	16
383	First-Line Systemic Treatment Strategies for Unresectable Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials. <i>Frontiers in Oncology</i> , 2021, 11, 771045.	1.3	20
384	Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?. <i>Frontiers in Oncology</i> , 2021, 11, 803133.	1.3	83
385	Upper Limits of Downstaging for Hepatocellular Carcinoma in Liver Transplantation. <i>Cancers</i> , 2021, 13, 6337.	1.7	3
386	Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma. <i>JAMA Network Open</i> , 2021, 4, e2136128.	2.8	29
387	Ðembrolizumab as second line therapy for hepatocellular patient. <i>Meditinskiy Sovet</i> , 2021, , 150-154.	0.1	0
388	Real-World Treatment Patterns and Health-Resource Utilization in Patients with Hepatocellular Carcinoma (HCC) Following Failure of Sorafenib: A Retrospective Chart Review of 127 Patients in South Korea. <i>Drugs - Real World Outcomes</i> , 2021, , 1.	0.7	0
389	Current status of first-line therapy, anti-angiogenic therapy and its combinations of other agents for unresectable hepatocellular carcinoma. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 2038-2049.	0.8	3
390	Biological therapies in patients with liver disease: are they really lifesavers?. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 473-490.	1.4	0

#	ARTICLE	IF	CITATIONS
392	Survival Outcomes and Safety of Programmed Cell Death/Programmed Cell Death Ligand 1 Inhibitors for Unresectable Hepatocellular Carcinoma: Result From Phase III Trials. <i>Cancer Control</i> , 2022, 29, 107327482210929.	0.7	4
393	Frontline therapy for advanced hepatocellular carcinoma: an update. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482210861.	1.4	13
394	Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States. <i>Hepatology</i> , 2022, 76, 1649-1659.	3.6	18
395	Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 2555-2566.	3.2	31
396	Sorafenib Versus Lenvatinib-Based Sequential Systemic Therapy for Advanced Hepatocellular Carcinoma: A Real-World Analysis. <i>Cancers</i> , 2022, 14, 1975.	1.7	5
397	Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2022, 16, 333-339.	1.4	65
398	Outcomes and Toxicities of Modern Combined Modality Therapy with Atezolizumab Plus Bevacizumab and Radiation Therapy for Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 1901.	1.7	15
399	Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials. <i>Clinical Cancer Research</i> , 2022, 28, 2297-2305.	3.2	8
400	Systemic Therapy in Metastatic Hepatocellular Carcinoma. <i>Current Gastroenterology Reports</i> , 2022, 24, 65-71.	1.1	4
401	Efficacy and safety of <sup>PD</sup>-1 inhibitor combined with antiangiogenic therapy for unresectable hepatocellular carcinoma: A multicenter retrospective study. <i>Cancer Medicine</i> , 2022, 11, 3612-3622.	1.3	13
405	Updates on clinical trials for the management of hepatocellular carcinoma. , 2022, , 259-273.		0
406	Application and Research Progress of Immunosuppressive Agent-Based Systemic System Therapy in Advanced Hepatocellular Carcinoma. <i>Advances in Clinical Medicine</i> , 2022, 12, 3079-3086.	0.0	0
407	Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience. <i>Investigational New Drugs</i> , 2022, 40, 789-797.	1.2	14
408	Advanced hepatocellular carcinoma: Impact of systemic treatments on healthâ€related quality of life and patientâ€reported outcomes. <i>Liver Cancer International</i> , 0, , .	0.2	1
409	An appraisal of FDA approvals for adult solid tumours in 2017â€2021: has the eagle landed?. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 486-492.	12.5	14
410	The Safety Profile of Hepatectomy Following Preoperative Systemic Therapy with Lenvatinib Plus Anti-PD-1 Antibodies Versus Hepatectomy Alone in Patients With Hepatocellular Carcinoma. <i>Annals of Surgery Open</i> , 2022, 3, e163.	0.7	5
411	Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. <i>Nature Cancer</i> , 2022, 3, 386-401.	5.7	126
412	Predictors of response for hepatocellular carcinoma immunotherapy: is there anything on the horizon?. <i>Expert Review of Precision Medicine and Drug Development</i> , 2022, 7, 50-57.	0.4	1

#	ARTICLE	IF	CITATIONS
415	Clinically approved combination immunotherapy: Current status, limitations, and future perspective. <i>Current Research in Immunology</i> , 2022, 3, 118-127.	1.2	20
416	An exploratory clinical trial of apatinib combined with intensity-modulated radiation therapy for patients with unresectable hepatocellular carcinoma. <i>Cancer Medicine</i> , 0, , .	1.3	5
417	Indonesian consensus on systemic therapies for hepatocellular carcinoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2023, 19, 263-274.	0.7	1
418	Safety and Efficacy of Sintilimab and Anlotinib as First Line Treatment for Advanced Hepatocellular Carcinoma (KEEP-G04): A Single-Arm Phase 2 Study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	22
419	Towards Immunotherapy-Induced Normalization of the Tumor Microenvironment. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, .	1.8	7
420	Emerging drugs for the treatment of hepatocellular carcinoma. <i>Expert Opinion on Emerging Drugs</i> , 2022, 27, 141-149.	1.0	4
421	Hepatotropic Peptides Grafted onto Maleimide-Decorated Nanoparticles: Preparation, Characterization and In Vitro Uptake by Human HepaRG Hepatoma Cells. <i>Polymers</i> , 2022, 14, 2447.	2.0	0
422	Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study. , 2022, 10, e004205.		26
424	Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	19
425	Second-line treatment of advanced hepatocellular carcinoma: Time for more individualized treatment options?. <i>World Journal of Hepatology</i> , 2022, 14, 1074-1086.	0.8	1
426	The presence and size of intrahepatic tumors determine the therapeutic efficacy of nivolumab in advanced hepatocellular carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211132.	1.4	10
427	TKIs beyond immunotherapy predict improved survival in advanced HCC. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	1
428	Intraarterial Therapies for the Management of Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 3351.	1.7	10
429	Computational Characterizing Necroptosis Reveals Implications for Immune Infiltration and Immunotherapy of Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
430	Non-alcoholic fatty liver disease-related hepatocellular carcinoma: Is there a role for immunotherapy?. <i>World Journal of Gastroenterology</i> , 2022, 28, 3595-3607.	1.4	1
431	Monocarboxylate transporter upregulation in induced regulatory T cells promotes resistance to anti-PD-1 therapy in hepatocellular carcinoma patients. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
432	Immune checkpoint inhibitors and tyrosine kinase inhibitors in patients with advanced hepatocellular carcinoma: Does the sequence matter?. <i>Asia-Pacific Journal of Clinical Oncology</i> , 0, , .	0.7	0
433	Protein Regulator of Cytokines 1 (PRC1) Upregulation Promotes Immune Suppression in Liver Hepatocellular Carcinoma. <i>Journal of Immunology Research</i> , 2022, 2022, 1-27.	0.9	1



#	ARTICLE	IF	CITATIONS
434	Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	90
435	Targeted Therapy for Hepatocellular Carcinoma: Old and New Opportunities. <i>Cancers</i> , 2022, 14, 4028.	1.7	25
436	Advances in novel systemic therapies for advanced hepatocellular carcinoma. <i>Future Medicinal Chemistry</i> , 0, , .	1.1	1
437	Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
438	What to do about hepatocellular carcinoma: Recommendations for health authorities from the International Liver Cancer Association. <i>JHEP Reports</i> , 2022, 4, 100578.	2.6	9
439	Polypharmacology in Clinical Applications“Anticancer Polypharmacology. , 2022, , 73-132.		0
440	Impact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: an international cohort study. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482211001.	1.4	5
441	Phase I/II Trial of Cabozantinib Plus Durvalumab in Advanced Gastroesophageal Cancer and Other Gastrointestinal Malignancies (CAMILLA): Phase Ib Safety and Efficacy Results. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
442	Phase 2 Study of the PD-1 Inhibitor Serplulimab plus the Bevacizumab Biosimilar HLX04 in Patients with Previously Treated Advanced Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2023, 12, 116-128.	4.2	5
443	Efficacy and safety of monotherapy and combination therapy of immune checkpoint inhibitors as first-line treatment for unresectable hepatocellular carcinoma: a systematic review, meta-analysis and network meta-analysis. <i>Discover Oncology</i> , 2022, 13, .	0.8	6
444	V-Set and immunoglobulin domain containing (VSIG) proteins as emerging immune checkpoint targets for cancer immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
445	Immunotherapy for nonalcoholic fatty liver disease-related hepatocellular carcinoma: Lights and shadows. <i>World Journal of Gastrointestinal Oncology</i> , 2022, 14, 1622-1636.	0.8	6
446	Advances and challenges of immunocheckpoint inhibitors in the treatment of primary liver cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
447	Efficacy and Safety of Regorafenib with or without PD-1 Inhibitors as Second-Line Therapy for Advanced Hepatocellular Carcinoma in Real-World Clinical Practice. <i>OncoTargets and Therapy</i> , 0, Volume 15, 1079-1094.	1.0	4
448	Addition of Camrelizumab to Transarterial Chemoembolization in Hepatocellular Carcinoma With Untreatable Progression. <i>Technology in Cancer Research and Treatment</i> , 2022, 21, 153303382211313.	0.8	6
449	Hepatocellular Carcinoma Medical Therapy. <i>Updates in Surgery Series</i> , 2023, , 173-179.	0.0	0
450	Surrogate end points for survival in patients with advanced hepatocellular carcinoma treated with immune checkpoint inhibitors. <i>Immunotherapy</i> , 2022, 14, 1341-1351.	1.0	9
451	Comparative efficacy and safety of atezolizumab and bevacizumab between hepatocellular carcinoma patients with viral and non“viral infection: A Japanese multicenter observational study. <i>Cancer Medicine</i> , 2023, 12, 5293-5303.	1.3	9

#	ARTICLE	IF	CITATIONS
452	An asparagine metabolism-based classification reveals the metabolic and immune heterogeneity of hepatocellular carcinoma. <i>BMC Medical Genomics</i> , 2022, 15, .	0.7	5
453	Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors. <i>Cancers</i> , 2022, 14, 5347.	1.7	8
454	Efficacy and Safety of PD-1/PD-L1 Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. <i>Advances in Therapy</i> , 0, , .	1.3	1
455	Interdisciplinary Approach in Hepatobiliary Cancers. , 2022, , 1-40.		0
456	Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study. , 2022, 10, e005457.		19
457	New Challenges Facing Systemic Therapies of Advanced HCC in the Era of Different First-Line Immunotherapy-Based Combinations. <i>Cancers</i> , 2022, 14, 5868.	1.7	5
458	Second-line treatment options for hepatocellular carcinoma: current state and challenges for the future. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 1151-1167.	1.9	3
459	Clinical value of identifying genes that inhibit hepatocellular carcinomas. <i>Expert Review of Molecular Diagnostics</i> , 2022, 22, 1009-1035.	1.5	1
460	Hepatocellular cancer of non-viral etiology: more questions than answers?. <i>Medical Alphabet</i> , 2022, , 7-12.	0.0	0
461	Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the firstâ€line treatment for unresectable hepatocellular carcinoma. <i>Cancer Medicine</i> , 2023, 12, 7077-7089.	1.3	10
462	Atezolizumab Plus Bevacizumab in Patients with Advanced and Progressing Hepatocellular Carcinoma: Retrospective Multicenter Experience. <i>Cancers</i> , 2022, 14, 5966.	1.7	11
463	MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma That Is Reversible through Restoration of Proinflammatory Macrophages. <i>Cancer Research</i> , 2023, 83, 626-640.	0.4	8
464	Overexpression of SMS in the tumor microenvironment is associated with immunosuppression in hepatocellular carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
465	Pathogenesis and Current Treatment Strategies of Hepatocellular Carcinoma. <i>Biomedicines</i> , 2022, 10, 3202.	1.4	26
467	Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
468	Clinical Outcomes Associated with Monotherapy and Combination Therapy of Immune Checkpoint Inhibitors as First-Line Treatment for Advanced Hepatocellular Carcinoma in Real-World Practice: A Systematic Literature Review and Meta-Analysis. <i>Cancers</i> , 2023, 15, 260.	1.7	1
469	Syngeneic N1-S1 Orthotopic Hepatocellular Carcinoma in Sprague Dawley Rat for the Development of Interventional Oncology-Based Immunotherapy: Survival Assay and Tumor Immune Microenvironment. <i>Cancers</i> , 2023, 15, 913.	1.7	3
470	Tumor immunology. , 2023, , 245-452.		0

#	ARTICLE	IF	CITATIONS
471	Analysis of angiogenesis-related subtypes of hepatocellular carcinoma and tumor microenvironment infiltration feature in hepatocellular carcinoma. <i>Clinical and Translational Oncology</i> , 0, , .	1.2	0
473	Cancer Immunology: Impact of Radioembolization of Hepatocellular Carcinoma on Immune Response Modulation. <i>American Journal of Roentgenology</i> , 2023, 220, 863-872.	1.0	5
474	TKIs in combination with immunotherapy for hepatocellular carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2023, 23, 279-291.	1.1	29
475	Survival Benefit of Experience of Liver Resection for Advanced Recurrent Hepatocellular Carcinoma Treated with Sorafenib: A Propensity Score Matching Analysis. <i>Current Oncology</i> , 2023, 30, 3206-3216.	0.9	0
476	Immunotherapy for hepatocellular carcinoma: Current status and future perspectives. <i>World Journal of Gastroenterology</i> , 0, 29, 1054-1075.	1.4	18
477	Effectiveness and safety of lenvatinib plus anti-programmed death-1 antibodies in patients with hepatocellular carcinoma: A real-world cohort study. <i>Cancer Medicine</i> , 2023, 12, 9202-9212.	1.3	3
478	The Multifaceted Roles of Macrophages in NAFLD Pathogenesis. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2023, 15, 1311-1324.	2.3	13
479	The Feasibility of TACE Combined with TKIs Plus PD-1 Antibody for Advanced HCC. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 10, 447-457.	1.8	1
480	The predictive value of PD-L1 expression in patients with advanced hepatocellular carcinoma treated with PD-1/PD-L1 inhibitors: A systematic review and meta-analysis. <i>Cancer Medicine</i> , 2023, 12, 9282-9292.	1.3	8
481	T cells in the heterogeneous tumour immune microenvironment of hepatocellular carcinoma: Implications for immune checkpoint inhibitor therapy. <i>Liver Cancer International</i> , 2023, 4, 58-72.	0.2	0
482	Effects of pegylated recombinant human granulocyte colony-stimulating factor on lymphocytes and white blood cells of patients with malignant tumor. <i>Open Life Sciences</i> , 2023, 18, .	0.6	2
483	Hepatocellular carcinoma (HCC) immunotherapy by anti-PD-1 monoclonal antibodies: A rapidly evolving strategy. <i>Pathology Research and Practice</i> , 2023, 247, 154473.	1.0	1